Charcoal for direct oral anticoagulant removal: toward appropriate prescribing and sustainable anticoagulation? [0.03%]
用于直接口服抗凝药物清除的木炭：合理用药和可持续抗凝的未来？
Nûn Kalim Bentounes,Nicolas Gendron
Nûn Kalim Bentounes
Refining thrombotic risk in membranous lupus nephritis: is anti-C1q the missing link? [0.03%]
狼疮性膜性肾炎的血栓风险评估：补体C1q抗体检测不容忽视？
Savino Sciascia,Maria Dall&#x;Era
Savino Sciascia
Katherine G Stevens,Matti F Pronker,Jan Voorberg
Katherine G Stevens
Intermediate-dose anticoagulation in COVID-19: closing the loop on a long-settled question [0.03%]
COVID-19的中剂量抗凝治疗：解决一个长期存在的问题
Behnood Bikdeli,Alex C Spyropoulos
Behnood Bikdeli
Felix Poppelaars,Bernardo Faria
Felix Poppelaars
Wolfgang Miesbach
Wolfgang Miesbach
Surgical and procedural bleed risk stratification for anticoagulated patients undergoing planned surgery: commentary on guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis [0.03%]
接受计划手术的抗凝患者的外科和操作出血风险分层：ISTH围术期和危重症血栓与止血亚专业委员会指南述评
Scott Kaatz
Scott Kaatz
Beyond echocardiography: rethinking postpulmonary embolism follow-up in light of European Society of Cardiology algorithms [0.03%]
超声心动图之外：欧洲心脏病学会算法指导下的肺栓塞后随访反思
Bibi Ayesha Bassa,Fionnuala Ní Áinle
Bibi Ayesha Bassa